RENX Renalytix Plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.…
Industry Peers
Health Information ServicesKey Statistics
About Renalytix (LON: RENX)
›
Renalytix (LON: RENX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Health Information Services industry, part of the Healthcare sector.
The shares were at 5.350 GBp on 19 November 2026, down 26.2% over 52 weeks. Its 52-week range is 1.600 GBp to 7.630 GBp: the price is 29.9% below the high and 234.4% above the low.
Its market capitalisation is 35.87M GBP.
Renalytix reports return on equity of 291.4%, an operating margin of -463.3% and revenue down 17.6% year over year.
Its debt exceeds its cash by 4.30M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.